tetano
Editor, Senior Moderator
Clin Infect Dis. 2019 Feb 2. doi: 10.1093/cid/ciz075. [Epub ahead of print]
[h=1]Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season.[/h] Rolfes MA[SUP]1[/SUP], Flannery B[SUP]1[/SUP], Chung J[SUP]1[/SUP], O'Halloran A[SUP]1[/SUP], Garg S[SUP]1[/SUP], Belongia EA[SUP]2[/SUP], Gaglani M[SUP]3[/SUP], Zimmerman R[SUP]4[/SUP], Jackson ML[SUP]5[/SUP], Monto AS[SUP]6[/SUP], Alden NB[SUP]7[/SUP], Anderson E[SUP]8[/SUP], Bennett NM[SUP]9[/SUP], Billing L[SUP]10[/SUP], Eckel S[SUP]11[/SUP], Kirley PD[SUP]12[/SUP], Lynfield R[SUP]13[/SUP], Monroe ML[SUP]14[/SUP], Spencer M[SUP]15[/SUP], Spina N[SUP]16[/SUP], Talbot HK[SUP]17[/SUP], Thomas A[SUP]18[/SUP], Torres S[SUP]19[/SUP], Yousey-Hindes K[SUP]20[/SUP], Singleton J[SUP]21[/SUP], Patel M[SUP]1[/SUP], Reed C[SUP]1[/SUP], Fry AM[SUP]1[/SUP]; U.S. Flu VE Network, the Influenza Hospitalization Surveillance Network (FluSurv-NET), and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] The severity of the 2017-2018 influenza season in the U.S. was high with influenza A(H3N2) viruses predominating. We report influenza vaccine effectiveness (VE) and estimate the number of vaccine prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for the 2017-2018 influenza season.
[h=4]Methods:[/h] We used national age-specific estimates of 2017-2018 influenza vaccine coverage and disease burden. We estimated VE, and 95% confidence intervals (CI), against medically-attended RT-PCR confirmed influenza virus infection, in the ambulatory setting, using a test-negative design. We estimated influenza type/subtype-specific burden using multipliers applied to population-based rates of influenza-associated hospitalizations. We used a compartmental model to estimate numbers, with 95% credible intervals (CrI), of influenza-associated outcomes prevented by vaccination.
[h=4]Results:[/h] The VE against outpatient medically-attended, laboratory-confirmed influenza was 38% (95% CI: 31-43%) including 22% (95% CI: 12-31%) against influenza A(H3N2), 62% (95% CI: 50-71%) against influenza A(H1N1)pdm09, and 50% (95% CI: 41-57%) against influenza B. We estimated that influenza vaccination prevented 7.1 million (95% CrI: 5.4 million-9.3 million) illnesses, 3.7 million (95% CrI: 2.8 million-4.9 million) medical visits, 109,000 (95% CrI: 39,000-231,000) hospitalizations, and 8,000 (95% CrI: 1,100-21,000) deaths. Vaccination prevented 10% of expected hospitalizations overall and 41% among young children (6 months-4 years).
[h=4]Conclusions:[/h] Despite 38% VE, influenza vaccination reduced a substantial burden of influenza-associated illness, medical visits, hospitalizations, and deaths in the U.S. during the 2017-2018 season. Our results demonstrate the benefit of current influenza vaccination and the need for improved vaccines.
PMID: 30715278 DOI: 10.1093/cid/ciz075
[h=1]Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season.[/h] Rolfes MA[SUP]1[/SUP], Flannery B[SUP]1[/SUP], Chung J[SUP]1[/SUP], O'Halloran A[SUP]1[/SUP], Garg S[SUP]1[/SUP], Belongia EA[SUP]2[/SUP], Gaglani M[SUP]3[/SUP], Zimmerman R[SUP]4[/SUP], Jackson ML[SUP]5[/SUP], Monto AS[SUP]6[/SUP], Alden NB[SUP]7[/SUP], Anderson E[SUP]8[/SUP], Bennett NM[SUP]9[/SUP], Billing L[SUP]10[/SUP], Eckel S[SUP]11[/SUP], Kirley PD[SUP]12[/SUP], Lynfield R[SUP]13[/SUP], Monroe ML[SUP]14[/SUP], Spencer M[SUP]15[/SUP], Spina N[SUP]16[/SUP], Talbot HK[SUP]17[/SUP], Thomas A[SUP]18[/SUP], Torres S[SUP]19[/SUP], Yousey-Hindes K[SUP]20[/SUP], Singleton J[SUP]21[/SUP], Patel M[SUP]1[/SUP], Reed C[SUP]1[/SUP], Fry AM[SUP]1[/SUP]; U.S. Flu VE Network, the Influenza Hospitalization Surveillance Network (FluSurv-NET), and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] The severity of the 2017-2018 influenza season in the U.S. was high with influenza A(H3N2) viruses predominating. We report influenza vaccine effectiveness (VE) and estimate the number of vaccine prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for the 2017-2018 influenza season.
[h=4]Methods:[/h] We used national age-specific estimates of 2017-2018 influenza vaccine coverage and disease burden. We estimated VE, and 95% confidence intervals (CI), against medically-attended RT-PCR confirmed influenza virus infection, in the ambulatory setting, using a test-negative design. We estimated influenza type/subtype-specific burden using multipliers applied to population-based rates of influenza-associated hospitalizations. We used a compartmental model to estimate numbers, with 95% credible intervals (CrI), of influenza-associated outcomes prevented by vaccination.
[h=4]Results:[/h] The VE against outpatient medically-attended, laboratory-confirmed influenza was 38% (95% CI: 31-43%) including 22% (95% CI: 12-31%) against influenza A(H3N2), 62% (95% CI: 50-71%) against influenza A(H1N1)pdm09, and 50% (95% CI: 41-57%) against influenza B. We estimated that influenza vaccination prevented 7.1 million (95% CrI: 5.4 million-9.3 million) illnesses, 3.7 million (95% CrI: 2.8 million-4.9 million) medical visits, 109,000 (95% CrI: 39,000-231,000) hospitalizations, and 8,000 (95% CrI: 1,100-21,000) deaths. Vaccination prevented 10% of expected hospitalizations overall and 41% among young children (6 months-4 years).
[h=4]Conclusions:[/h] Despite 38% VE, influenza vaccination reduced a substantial burden of influenza-associated illness, medical visits, hospitalizations, and deaths in the U.S. during the 2017-2018 season. Our results demonstrate the benefit of current influenza vaccination and the need for improved vaccines.
PMID: 30715278 DOI: 10.1093/cid/ciz075